Breaking News

Pluristem Completes New Manufacturing Facility

December 28, 2012

Initiates final validation steps

Pluristem Therapeutics, Inc. has initiated the final validation steps for its new manufacturing facility, including the validation of several installation systems such as heating, ventilation and air conditioning (HVAC), water, oil free air and sterile room systems.
 
Zami Aberman, chairman and chief executive officer of Pluristem, said, "I am extremely proud of our team in meeting milestones for the completion of the world's first commercial cell therapy manufacturing facility. Assuming the PLX cells product candidates are successfully developed and approved by the regulators, we believe that the new facility would have the capacity to produce PLX cells for the treatment of over 150,000 patients annually estimated by Pluristem at $1 billion in production value. Additionally, as clinical trials are approved by regulators for additional indications, our new facility will enable us to supply PLX cells to conduct these trials in parallel."
 

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.